中国低月龄婴儿麻疹疫苗接种的成本效果分析
该研究针对中国麻疹消除目标下8月龄以下婴儿易感问题,采用决策分析模型比较将首剂麻疹疫苗提前至4、5、6或7月龄接种与现行8月龄接种的成本与健康效益。结果显示提前接种以极小成本带来增量健康收益,4月龄接种的增量成本效果比最优(每获得一个QALY增加232.70美元)。
要点
- 将首剂麻疹疫苗提前至8月龄前可带来增量健康收益,个体层面成本增加极小。
- 4月龄接种的ICER最优,为每QALY增加232.70美元,因可依托现有免疫规划访视减少增量项目成本。
- 需进一步研究疾病传播动力学以全面评估低月龄接种的权衡。
核心结论
- 在中国将麻疹疫苗首剂提前至8月龄前接种可能以最低成本获得健康收益。
研究设计与样本
- 成本效用分析,基于Microsoft Excel构建决策分析模型,比较4、5、6或7月龄接种首剂与现行8月龄接种方案。
- 模型纳入五种非重症和两种致死性麻疹感染健康结局,参数来自文献和监测数据,未来成本与健康效益按3%贴现,终身时间 horizon。
主要发现
- 将麻疹疫苗系列起始推荐年龄降低以应对8月龄以下儿童易感性,相比现行方案在个体层面以极小成本提供增量健康收益。
- 4月龄接种首剂的ICER最有利,为每QALY增加232.70美元,因将麻疹接种转移至中国免疫规划已建立的免疫访视而减少增量项目成本。
关键数值与推荐
- 4月龄接种首剂的ICER为232.70美元/QALY gain。
- 未来成本与健康效益贴现率3%。
临床怎么用
- 可为考虑将麻疹疫苗首剂提前至8月龄前(尤其是4月龄)提供成本效果证据参考。
- 实施前需结合本地麻疹传播动力学和免疫规划访视安排进一步评估。
局限性
- 需进一步研究疾病传播动力学以更全面评估低月龄接种的权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although global progress in measles control has been realized, achieving elimination has proven difficult in many regions of the world. China has adopted a goal of measles elimination but recent outbreaks predominantly affecting children <8 months who are ineligible for vaccination and incompletely protected by maternal antibodies has impeded progress. We assess the cost-effectiveness of adding an initial measles vaccine dose in China to earlier than the currently recommended 8 months of age. METHODS: We conducted a cost-utility analysis comparing the costs and health benefits associated with adding a measles vaccine dose to the routine schedule at 4, 5, 6 or 7 months compared to the current recommendation for the first dose at age 8 months. A decision analytic model was developed in Microsoft Excel, including five non-severe and two fatal health outcomes associated with measles infection. Model parameters were informed by the literature and surveillance data. Future costs and health benefits were discounted at 3%. Primary outcomes included costs, Quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) over a lifetime time horizon. RESULTS: Lowering the recommended age for initiating the measles vaccination series to address susceptibility in children <8 months provided incremental health gains compared to minimal costs at the individual-level. The ICER was most favorable ($232.70 per QALY gain) for administering an initial dose at 4 months of age due to fewer incremental program costs when shifting measles administration to an immunization visit already established under the Chinese vaccination program. CONCLUSION: We found potential beneficial health gains at a minimum cost associated with adding an earlier measles dose <8 months of age in China. Further investigation about disease transmission dynamics is required to more fully assess the tradeoffs of administering measles at a younger age to infants in China.
引用
- Janusz CB, Wagner AL, Masters NB, et al. Measles vaccination of young infants in China: A cost-effectiveness analysis. Vaccine. 2020. PMID: 32451210. doi:10.1016/j.vaccine.2020.04.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。